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Mouse models of Alzheimer’s disease have served as valuable tools for investigating pathogenic mech-
anisms relating to neurodegeneration, including tau-mediated and neuroﬁbrillary tangle pathologyda
major hallmark of the disease. In this work, we have used multiparametric magnetic resonance imaging
(MRI) in a longitudinal study of neurodegeneration in the rTg4510 mouse model of tauopathy, a subset of
which were treated with doxycycline at different time points to suppress the tau transgene. Using this
paradigm, we investigated the sensitivity of multiparametric MRI to both the accumulation and sup-
pression of pathologic tau. Tau-related atrophy was discernible from 5.5 months within the cortex and
hippocampus. We observed markedly less atrophy in the treated rTg4510 mice, which was enhanced
after doxycycline intervention from 3.5 months. We also observed differences in amide proton transfer,
cerebral blood ﬂow, and diffusion tensor imaging parameters in the rTg4510 mice, which were signiﬁ-
cantly less altered after doxycycline treatment. We propose that these non-invasive MRI techniques offer
insight into pathologic mechanisms underpinning Alzheimer’s disease that may be important when
evaluating emerging therapeutics targeting one of more of these processes.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
It has been over a century since Alois Alzheimer ﬁrst described
the symptoms of the presenile dementia that would come to bear
his name (Stelzmann et al., 1995); but to date, there is still no
disease-modifying or preventative treatment for this devastating
disease. As the incidence of Alzheimer’s disease (AD) continues to
rise to epidemic proportions (Brookmeyer et al., 2007), effective
therapies are urgently required to ease both the economic and
emotional burdens of this devastating disease.medical Imaging, University
St, London WC1E 6DD, UK.
s).
Inc. This is an open access articleThe two key neuropathologic hallmarks of AD are plaques
comprised of amyloid-beta (Ab) peptides and neuroﬁbrillary tan-
gles (NFTs) of hyperphosphorylated tau. Emerging therapies tar-
geting the production or clearance of these protein aggregates
require robust biomarkers to evaluate and quantify therapeutic
efﬁcacy. The development of reliable biomarkers in humans, how-
ever, is complicated by the length of the clinical studies required to
follow the evolution of pathology; this is currently believed to occur
as much as 30e40 years before cognitive deﬁcits (Jack et al., 2013).
One approach is to establish and validate biomarkers using mouse
models of AD as a surrogate for patient populations.
Transgenicmousemodels of AD have served as valuable tools for
investigating pathogenic mechanisms relating to neuro-
degeneration. Mice containing mutations in the amyloid precursor
protein (APP) gene are the oldest and most widely studied models
of AD and are used to investigate the role of APP, Ab, andunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Despite compelling evidence suggesting that Ab may be the pri-
mary cause of AD, the therapeutic efﬁcacy of Ab immunization
observed in animal models of AD has yet to be translated success-
fully in patients with AD (Giacobini and Gold, 2013). Tau pathology,
not Ab burden, independently predicts cognitive status in patients
with AD (Giannakopoulos et al., 2003). This suggests the potential
value of tau-targeted therapies in AD and the requirement for non-
invasive biomarkers that are sensitive to the severity of tau
pathology.
To investigate tau-speciﬁc biomarkers of pathology, we have
used the tetracycline operator-MAPT*P301L (or rTg4510) mouse
model (Ramsden et al., 2005), which expresses a repressible form of
the human P301L mutant of the 4-repeat microtubule-associated
protein tau (MAPT) gene, under the control of a tetracycline-
responsive element. The rTg4510 mouse develops robust NFT pa-
thology in the forebrain around 4 months of age, with the cortex
and hippocampus being severely affected (SantaCruz et al., 2005), a
distribution similar to that seen in AD patients (Braak and Braak,
1995). One advantage of the model is that the expression of
mutant tau can be effectively suppressed by the administration of
the tetracycline derivative doxycycline (SantaCruz et al., 2005).
Longitudinal assessment of this model enables the investigation of
biomarkers sensitive to the accumulation of tau pathology and
provides a framework to evaluate the efﬁcacy of therapeutic stra-
tegies targeted at the suppression or removal of pathologic tau.
In this work, we sought to identify speciﬁc elements of the
pathologic cascade and the advancement and inhibition of tau pa-
thology, using multiparametric magnetic resonance imaging (MRI)
measures in the rTg4510mouse. We exploredmorphologic changes
using high-resolution structural MRI, the breakdown in chemical
exchange of mobile proteins using amide proton transfer (APT)
imaging, microstructural changes in the cytoarchitecture through
diffusion tensor imaging (DTI), and alterations in cerebral blood
ﬂow (CBF) using arterial spin labelling (ASL), over time.
The rTg4510 mouse accumulates an early burden of tau pa-
thology, which progresses rapidly (SantaCruz et al., 2005). Pre-
tangles, a premature state to NFTs, have been observed from 2.5
months, followed by mature tangle formations between 3 and 5.5
months of age (Yue et al., 2011). To coincide with the progressive
and dynamic accumulation of tau pathology in this model, we
conducted 2 longitudinal studies: one group received doxycycline
from 3.5 months and the second cohort received doxycycline from
4.5 months. Using these multiparametric MRI techniques, we
demonstrate sensitivity to tau-driven pathologic changes and tau
suppression in the rTg4510 in mice treated at 2 distinct time points.
2. Materials and methods
2.1. Animals
The rTg4510 animal model used in this study has been previ-
ously characterized and described in the literature, predominantly
by using histologic techniques (SantaCruz et al., 2005). Female
rTg4510 mice and litter-matched wild-type controls were bred on a
mixed FVB/NCrl þ 129S6/SvEvTa background for Eli Lilly and
Company by Taconic (Germantown,MD, USA) and received on site 2
weeks before the initiation of the studies.
Two doxycycline intervention cohorts are reported in this study
and summarized inSupplementaryFig.1. The3.5-month intervention
cohort consisted of 20 rTg4510 mice with 10 wild-type controls, and
the 4.5-month intervention cohort consisted of 19 rTg4510micewith
11 wild-type controls. Subsequent to their initial scan, the rTg4510
mice were divided into 2 subgroups: the treated rTg4510 mice
received 2 boluses of 10mg/kg doxycycline hyclate (SigmaAldrich,10mg per kg of body weight) via oral gavage and were maintained on
doxycycline-mixed chow diet (Harlan Teklad Rodent Diet, 200 mg
doxycycline per kg of dietary chow) until the end of the study and the
untreated rTg4510mice and thewild-type controls received2boluses
of a 5% glucose vehicle via oral gavage and were maintained on
standard chow. The dietary content of the doxycycline-mixed and
standard chow was consistent for each group.
For further evaluation of the rTg4510 mouse’s response to
increasing concentrations of isoﬂurane, a separate cohort of female
rTg4510 mice and wild-type controls were imaged at 9 months.
All mice were kept in standard size mouse cages (29  18  13
cm, up to 5 per same sex groups) at 20e26 C on a daily 12-hour
light-dark cycle with ad libitum access to food and water. All
studies were carried out in accordance with the UK Animals (Sci-
entiﬁc Procedures) Act of 1986 and subject to approval by the in-
ternal ethical review panel of University College London.
2.2. Magnetic resonance imaging
All imaging was performed with a 9.4-T VNMRS horizontal bore
scanner (Agilent Inc). A 72-mm inner diameter volume coil (Rapid
Biomedical) was used for radiofrequency transmission, and signal
was received using a 4-channel array head coil (Rapid Biomedical).
Mice were placed in an induction box before anesthesia was
induced using 2% isoﬂurane at 1 L per minute in 100% O2. Mice were
subsequently positioned in an MRI-compatible head holder to
minimize motion artifacts. Anesthesia was maintained throughout
imaging using 1.5% (0.2%) isoﬂurane at 1 L per minute in 100% O2
delivered via a nose cone, which permitted spontaneous breathing
of the mice. Core temperature and respiratory rate were monitored
using a rectal probe and pressure pad, respectively (SA In-
struments). Mice were maintained at w37 C using heated water
tubing and a warm air blower with a feedback system (SA In-
struments). Respiration rate was maintained between 80 and 120
breaths per minute by manually adjusting the isoﬂurane vaporizer.
Scans were performed in the following order: chemical exchange
saturation transfer (CEST), ASL, DTI, and structural imaging. Before
imaging, shimmingwas ﬁrst performed across a volume speciﬁcally
conﬁned to the CEST imaging slice (3 mm slice thickness [coronal]).
After CEST acquisition, shimming was performed across the whole
mouse brain for the structural, ASL, and DTI sequences.
Mice within the 3.5-month intervention cohort were scanned at
baseline (3.5 months) and subsequently at 5.5 and 7.5 months. Mice
within the 4.5-month intervention cohort were scanned at baseline
(4.5 months) and subsequently at 7.5 months. In both studies,
administration of doxycycline was commenced after the baseline
scan. All animals were perfuse ﬁxed after the ﬁnal imaging time
point at 7.5 months before histologic evaluation (see Section 2.7).
We employed high-resolution structural MRI, CEST, DTI, and ASL at
each time point to characterize the treated and untreated rTg4510
mice and wild-type controls.
2.3. Structural imaging
A 3-dimensional T2-weighted fast spin echo sequence was
employed for structural imaging with the following parameters:
ﬁeld of view (FOV) ¼ 19.2  16.8  12.0 mm, resolution ¼ 150 
150150 mm, repetition time (TR)¼ 2500ms, effective echo time¼
43 ms, echo train length ¼ 4, number of signal averages ¼ 1, and
imaging time ¼ 1.5 hours.
2.3.1. Processing for tensor-based morphometry
At each time point, the in vivo structural images were auto-
matically oriented to a standard atlas space (right anterosuperior),
corrected for intensity nonuniformity using the N4ITK algorithm
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rithm, STEPS (Jorge Cardoso et al., 2013), combining masks from
several prior atlases registered to the data. Intensities were
normalized (Nyul et al., 2000), and a multi-iteration group-wise
registration (implemented in the open-source NiftyReg software
(Modat et al., 2010) was performed as follows to align equivalent
voxels between subjects. First, all subjects were rigidly aligned to a
randomly chosen target member of the group. This was followed by
4 iterations of afﬁne registration (12 of freedom), using a block-
matching algorithm to optimize normalized mutual information
and 15 iterations of non-rigid registration, based on symmetric
free-form deformation (Modat et al., 2012). After each iteration, the
intensity average image was calculated and used as the target for
the subsequent registrations. The determinant of the Jacobian
matrix was calculated at each voxel of the resulting deformation
ﬁelds, giving that voxel’s relative expansion or contraction in the
space of the ﬁnal average. These values were smoothed with a 0.2-
mm full-width half-maximum Gaussian kernel to account for
registration error and log transformed. Mass-univariate statistics
(2-tailed t tests) were performed at each voxel, ﬁtting a general
linearmodel to compare groups. The resulting statistical parametric
maps were corrected for multiple tests using the false discovery
rate (Genovese et al., 2002, q ¼ 0.05).
2.3.2. Automatic structural parcellation
Using a multiatlas-based structural parcellation framework
(Ma et al., 2014), we extracted 3 structures of interest: the cortex,
hippocampus, and thalamus for each animal at each time point. The
brain images were oriented, nonuniformity corrected, and skull
stripped, as earlier. We adopted the publicly available in vivo mouse
brain MRI atlas previously published by Ma et al. (2008) for the
framework. First, the atlas images were registered afﬁnely to the
original MRI image data using a block-matching algorithm
(Ourselin et al., 2000). Once complete, the STAPLE algorithm (Ma
et al., 2014) was applied to fuse the resampled atlas masks
together to create a consensus brainmask for each animal’s scans. A
further non-rigid registration based on fast free-form deformation
was then performed to correct any remaining local misalignment of
the afﬁnely registered atlas to the brain volumes (Modat et al.,
2010). The structural labels from the atlas were then resampled to
match the resolution of the brain scans and fused using the STEPS
algorithm (Jorge Cardoso et al., 2013) to create the ﬁnal parcellated
structures of interest: the cortex, hippocampus, and thalamus. A
previously published calibration protocol was used to correct
gradient scaling errors in the data (O’Callaghan et al., 2014). Abso-
lute volumes were normalized to the total brain volume to calculate
the normalized volume change. Two-way analysis of variance t tests
were applied to volumes of structures of interest, for each animal in
each group at its corresponding time point. The Tukey range test
was applied to correct for multiple comparisons.
2.4. Chemical exchange saturation transfer
The CEST sequence was acquired using a single slice gradient
echo imaging sequence positioned axial using the splenium of the
corpus callosum as a landmark for consistency of slice positioning
between subjects (TR ¼ 6.1 ms, echo time ¼ 2 ms, ﬂip ¼ 5, FOV ¼
20  20 mm, slice thickness ¼ 3 mm, matrix size ¼ 64  64).
Saturation pulses were applied at 79 frequency offsets covering 6
ppm to encompass APT saturation peaks around þ3.5 ppm. A
reference offset at 200 ppm was also acquired for normalization.
APT was calculated as the area under the MTRasym curves between
3.3 and 3.7 ppm on a pixel-by-pixel basis by ﬁtting a polynomial
function to Z spectra, correcting for off-resonance effects by cubic
spline interpolation and subtracting the signal intensities at eitherside of the direct water saturation peak (van Zijl and Yadav, 2011).
Total imaging time was 5 minutes.
2.5. Diffusion tensor imaging
A 4-shot spin echo echo planar imaging sequence was used to
acquire 16 slices. The ﬁssure between the olfactory bulbs and the
cortex was used as an anatomic landmark to maintain consistency
in slice positioning between animals. The FOV was 20  20 mm
with a matrix size of 100  100 and a slice thickness of 0.5 mm.
Diffusion gradients were applied in 20 directions with the following
parameters G ¼ 0.25 T/m, D ¼ 9.3 ms, d ¼ 5.5 ms, and b ¼ 1050
seconds per mm2 to generate diffusion-weighted images in addi-
tion to a single unweighted B0 image. Acquisition of 5 averages with
a TR of 2000 ms gave a total imaging time of 30 minutes. Software
written in Matlab was used to construct tensors at each voxel
through a least-squares solution approach (Batchelor et al., 2003).
The parameters fractional anisotrophy (FA), mean diffusivity (MD),
and radial diffusivity (RD) were calculated from the tensors
following standard methods (Le Bihan et al., 2001; Song et al.,
2002). Total imaging time was 25 minutes.
2.6. Arterial spin labelling
A ﬂow-sensitive alternating inversion recovery sequence (Kim,
1995; Kwong et al., 1992) with a 4-shot segmented spin echo
echo planar imaging readout was implemented with the
following parameters: 5 slices, slice thickness ¼ 1 mm, FOV ¼ 20 
20 mm, matrix size ¼ 64  64, slice selective inversion pulse
width¼ 12mm, inversion time¼ 1500ms, echo time¼ 11ms, TR¼
3500 ms, and 20 averages. A hyperbolic secant adiabatic inversion
pulse was used with a bandwidth of 20 kHz for the ﬂow-sensitive
alternating inversion recovery labelling pulses (Wells et al., 2012).
The splenium of the corpus callosum was used as a landmark for
consistency of slice positioning between subjects. Total imaging
time was 20 minutes. CBF maps were generated using the model
described by Buxton et al. (1998).
2.7. Perfuse ﬁxation
After in vivo imaging, mice were terminally anesthetized with
euthanal (0.1 mL) administered via intraperitoneal injection. The
thoracic cavities were opened and the mice perfused through the
left ventricle with 15e20 mL of saline (0.9%) followed by 50 mL of
buffered formal saline at a ﬂow rate of 3 mL per minute. After
perfusion, the animal was decapitated, deﬂeshed, and the lower jaw
removed. All brains were stored in-skull at 4 C before being dis-
patched for histology.
2.8. Histology and immunohistochemistry
Brain samples were processed using the Tissue TEK VIP pro-
cessor (GMI Inc, Ramsey, MN, USA) before being embedded in
parafﬁn wax for coronal brain sectioning. Serial sections (6 mm)
were taken using HM 200 and HM 355 (Thermo Scientiﬁc Microm,
Germany) rotary microtomes. Immunohistochemistry (IHC) was
performed using a primary antibody for tau phosphorylated at
serine 409 (PG-5, 1:500 from Peter Davies; Albert Einstein College
of Medicine, Bronx, NY, USA) as previously described (Ahmed et al.,
2014). Stained sections were digitized using the Scanscope XT slide
scanner (Aperio, Vista, CA, USA) at 20 magniﬁcation. Imagescope
software (version 11.1.2.760; Aperio) was used to view the digitized
tissue sections and delineate the regions of interest (ROIs) (cortex,
hippocampus, and thalamus). The number of PG-5epositive neu-
rons was manually counted within a delineated region and
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and averaged before statistical analysis.2.9. Statistical analysis
For the structural parcellation analysis, the volumes of the cor-
tex, hippocampus, and thalamus represent the whole respective
structures. For the CEST, DTI, and ASL analysis, measurements were
taken from ROIs drawn in a single slice positioned approximately
bregma e2.3; this was to align our MRI measurements with the
coronal section that was used to quantify NFT burden in our his-
tologic analysis. ROIs were manually drawn in the cortex, hippo-
campus, thalamus, and corpus callosum (DTI only), as illustrated in
Supplementary Fig. 2. The results within the hippocampus and
cortex were averaged to calculate parameters within regions
suffering from “high” levels of tau pathology.
Quantitative data were analyzed using Student t test for pair-
wise comparisons and 2-way analysis of variance, followed by Sidak
post hoc tests for group-wise comparisons. GraphPad Prism 5
(version 5.04; GraphPad Software Inc, La Jolla, CA, USA) was used to
perform statistical tests and to produce graphs, which displaymean
values  standard deviation (SD). Statistical signiﬁcance was set at
p  .05.3. Results
In this work, we have explored the sensitivity of multi-
parametric MRI to the accumulation and suppression of pathologic
tau. A detailed description of the imaging protocol is provided inFig. 1. Immunohistochemistry to estimate regional tau phosphorylated at serine 409 (PG-
trating the distribution of PG-5 positive NFTs in the untreated rTg4510s, with visible regiona
(B), hippocampal (C), and thalamic (D) NFT density for each of the wild-type (n ¼ 21), un
intervention rTg4510s (n ¼ 10) at 7.5 months of age. The y axis has been independently adjus
Error bars represent the standard deviation. **p  .01 and ****p  .0001.Supplementary Fig. 1, including the 3.5- and 4.5-month interven-
tion strategies.3.1. Histology and IHC
To quantify the severity of tau pathology in the doxycycline-
treated and untreated rTg4510 groups, all mice (n ¼ 21 wild-type,
23 untreated, 10 rTg4510 [3.5 months intervention] and 6 rTg4510
[4.5 months intervention]) were sacriﬁced after the ﬁnal imaging
time point (7.5 months) and prepared for neuropathologic assess-
ment. IHC using PG-5 (pS409), a marker of tau hyper-
phosphorylation, was used to quantify the density of tau-positive
neurons in the cortex, hippocampus, and thalamus (Fig. 1A); the
results can be seen in Fig. 1. Consistent with the literature
(SantaCruz et al., 2005), untreated rTg4510 mice contained a high
density of PG-5 positive neurons in the cortex and hippocampus
(mean ¼ 345.2  43.8 and 103.3  33.3 [SD], respectively,
Fig. 1AeC). In contrast, the thalamus had a signiﬁcantly lower
density (mean ¼ 5.34  2.8 [SD], Fig. 1A and D). For this reason, we
classiﬁed the cortex and hippocampus as “high tau burden” regions
and the thalamus as a “low tau burden” region. There was no PG-
5epositive staining observed in the wild-type mice. (Fig. 1BeD).
After administration of doxycycline to rTg4510 mice, we
observed a signiﬁcant reduction in the number of PG-5epositive
neurons in the cortex, hippocampus, and thalamus of the 3.5-
month intervention (p < .0001) and 4.5-month intervention (p <
.001, p < .05, and p < .01, respectively) mice compared with the
untreated group (Fig. 1AeD). The group treated with doxycycline
from 3.5 months showed the greatest reduction in PG-5epositive
neuron density, especially in the hippocampus and thalamus5)epositive neuroﬁbrillary tangle (NFT) density. (A) Representative coronal slice illus-
l speciﬁcity in treated and untreated animals. Quantitative regional estimates of cortical
treated rTg4510s (n ¼ 20), 4.5 months intervention Tg4510s (n ¼ 6), and 3.5 months
ted for each region under investigation to account for the marked range in PG-5 density.
H.E. Holmes et al. / Neurobiology of Aging 39 (2016) 184e194188regions, illustrating the effectiveness of earlier intervention in this
model.
3.2. High-resolution structural MRI
To investigate morphometric changes in the rTg4510 mice, we
acquired high-resolution in vivo 3-dimensional structural images
for the 2 longitudinal cohorts. We employed tensor-based
morphometry (TBM) to identify local areas of signiﬁcant brain at-
rophy or expansion; the results at 7.5 months are shown in Fig. 2.
For each set of comparisons, we present 3 coronal slices with TBM
statistics overlaid. Extensive bilateral morphometric changes were
detected in the untreated rTg4510 mice compared with wild-type
controls, including signiﬁcant atrophy in the forebrain, cortex,
lateral striata, and hippocampus and expansion of the lateral, third,
and fourth ventricles (Fig. 2A). Reductionswere also observed in the
thalamus; in the absence tau pathology in this region, this is likely
to reﬂect global differences in brain volume of the rTg4510 mice
compared with wild-type controls.
To investigate the morphologic changes within the 2
doxycycline-treated rTg4510 mice cohorts, we made 2 compari-
sons: ﬁrst, wild-type versus doxycycline-treated rTg4510 mice
(Fig. 2B and C), and second, untreated rTg4510 versus the treated
rTg4510 mice (Fig. 2D and E). In rTg4510 mice treated with doxy-
cycline from 3.5 months, we observed small discrete structural
changes within the caudate putamen and the hippocampus
compared with wild-type controls (Fig. 2B), indicating preservation
of cortical regions and ventricular spaces that presented with
markedly fewer signiﬁcant voxels. Figure 2D comparesmice treated
with doxycycline from 3.5 months with untreated rTg4510 mice.
Here, TBM detected gross relative expansion of the ventricles and a
bilateral pattern of cortical atrophy, highlighting regions preserved
because of suppression of the tau transgene. After administration of
doxycycline from 4.5 months, a similar yet more marked pattern of
changes was observed in comparison with wild-type controls
(Fig. 2C). The comparison between rTg4510 mice treated with
doxycycline from 4.5 months and untreated rTg4510 mice revealed
a small number of signiﬁcant voxels within the hippocampus,
indicating minor differences between these 2 cohorts (Fig. 2E); theFig. 2. Structural analysis at 7.5 months, showing tensor-based morphometry statistical res
iterations of non-rigid registration. Red: regions where the rTg4510 brains are relatively loc
discovery rateecorrected t statistics (q ¼ 0.05). (For interpretation of the references to coloearlier (3.5 months) intervention appeared more successful at
limiting atrophy and ventricular expansion.
At 5.5 months (Supplementary Fig. 3B), TBM detected compa-
rable yet less widespread differences between the wild-type and
rTg4510mice treatedwith doxycycline from3.5months in the same
regions implicated in Fig. 2. In the comparison between the un-
treated rTg4510 and rTg4510 mice treated with doxycycline from
3.5 months (Supplementary Fig. 3C), no signiﬁcant voxels survived
false discovery rate correction. TBM results at the baseline scan
revealed negligible signiﬁcant local differences between the
rTg4510 mice and wild-type controls (data not shown).
To quantify longitudinal volume differences between the
rTg4510 mice and wild-type controls in the regions selectively
vulnerable to high tau accumulation, we also employed a fully
automated atlas-based brain segmentation pipeline to measure
absolute and normalized volume changes in the high-ranked pa-
thology regions across all time points. Normalized volume changes
were calculated from the regional volume changes divided by the
change in the whole brain volume (to account for changes in whole
brain volume).
We detected a signiﬁcant reduction in absolute volume of the
high-ranked pathology regions within the untreated rTg4510 mice
from 3.5 months of age compared with the wild-type controls (p <
.001) (Fig. 3A). The absolute volume of the high-ranked pathology
regions within the untreated rTg4510 mice continued to decline by
a further 16.2% until the ﬁnal imaging time point at 7.5 months
(Fig. 3A). The rTg4510 mice treated with doxycycline from 3.5
months suffered less atrophy compared with the untreated
rTg4510 mice; the decline in volume was reduced to 6.3% owing to
the suppression of the transgene with doxycycline (Fig. 3A).
Meanwhile, the absolute volume of the wild-type controls
remained consistent from 3.5 months (82.1 mm3) to 7.5 months
(83.8 mm3) indicating that the volume changes were speciﬁc to
the rTg4510 mice (Fig. 3A). A similar trend was observed within
the untreated rTg4510 mice in the 4.5-month intervention study
(Fig. 3C).
We observed that the volume of the thalamus, a region of low
tau burden, was reduced in the rTg4510 mice compared with wild-
type controls from 3.5 months (Supplementary Fig. 4A); theseults overlaid on representative coronal slices of the ﬁnal group average images after 15
ally smaller than the average and blue: rTg4510 brains are locally larger. Based on false
r in this ﬁgure legend, the reader is referred to the Web version of this article.)
Fig. 3. Longitudinal volumetric changes, extracted from the high-resolution structural
images. Hippocampal and cortical volumes were averaged to extract absolute and
normalized volume changes in the high-ranked pathology regions. We present the
absolute volume changes within the high-ranked pathology regions after (A) 3.5
months and (C) 4.5 months intervention. In addition, we normalized the absolute
volume changes to the total brain volume to extract the normalized volume changes
after (B) 3.5 months and (D) 4.5 months intervention. Statistically signiﬁcant groups
have been identiﬁed and highlighted. Error bars represent the standard deviation.
Wild-type versus untreated rTg4510s: **p  .01, ***p < .001, and ****p  .0001. Wild-
type versus treated rTg4510s: þp  .05 and þþþþp  .0001. Treated rTg4510s versus
untreated rTg4510s: p  .01 and p  .0001.
Fig. 4. Longitudinal amide proton transfer (APT) results from the high-ranked pa-
thology regions after (A) 3.5 months and (B) 4.5 months doxycycline intervention.
Statistically signiﬁcant groups have been identiﬁed and highlighted. Error bars repre-
sent the standard deviation. Wild-type versus untreated rTg4510s: *p  .05 and **p 
.01. Treated rTg4510s versus untreated rTg4510s: p  .01.
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tau burden regions (Fig. 3A and C). This result, in the absence of tau
pathology, may indicate the effect of the transgene expression on
brain morphology, resulting in volume reduction in regions unaf-
fected by tau pathology (Supplementary Fig. 4A and C).
To uncover tau-speciﬁc volume changes and remove the con-
founding effects of the transgene expression, we also explored the
normalized volume changes. After normalization of the absolute
volumes to total brain volume at each time point, we detected
signiﬁcant volume loss in the high ranked pathology regions of the
untreated rTg4510 mice compared with wild-type controls at 7.5
months (p< .0001) (Fig. 3B and D). Atrophywas detectable from 5.5
months within these mice (p < .001) illustrating the sensitivity of
high-resolution structural MRI to tau-speciﬁc morphologic changes
occurring in the rTg4510 mice (Fig. 3B).
After treatment with doxycycline, we observed signiﬁcantly less
atrophy in the treated rTg4510 mice compared with the untreated
rTg4510 mice at 7.5 months (p < .0001), after both 3.5 and 4.5
months doxycycline intervention (Fig. 3B and D). Interestingly, the
atrophy within the mice treated from 3.5 months was signiﬁcantly
less than rTg4510 mice treated from 4.5 months: 7.0% and 12.4%
volume loss, respectively. These results suggest that earlier inter-
vention was able to reduce atrophy to a greater extent.
Normalization of the thalamus to total brain volume resulted in
an expected (as this region suffers little tau pathology) increase in
normalized thalamic volume within the rTg4510 mice compared
with the wild-type controls (Supplementary Fig. 4B and D). This is
because of normalization with the decreasing total brain volume,
leading to an apparent increase in thalamic volume over time.3.3. Chemical exchange saturation transfer
Figure 4A shows the CEST results within the high-ranked pa-
thology regions of the rTg4510 mice after doxycycline intervention
from 3.5 months. Decreased APT was identiﬁed in the untreated
rTg4510 mice relative to the wild-type controls at 7.5 months (p <
.01). Within the thalamus, in the presence of low tau burden, APT
was not signiﬁcantly different between the rTg4510 animals and
wild-type controls (Supplementary Fig. 5). These results provide
evidence in support of APT’s sensitivity to tau-related pathology at
later time points.
Administration of doxycycline, after both 3.5 and 4.5 months
intervention, resulted in an increase in APT towardwild-type values
by 7.5 months. At this time point, APT in the treated rTg4510 mice
was not signiﬁcantly different from the wild-type controls (Fig. 4A
and B). The rTg4510mice treated with doxycycline from 3.5 months
showed greater conservation: at this time point, both the treated
rTg4510 mice and the wild-type controls were signiﬁcantly
different from the untreated rTg4510 mice (p < .01) (Fig. 4A). This
indicates that the APT signal may be sensitive to the suppression of
pathologic conformations of tau.3.4. Diffusion tensor imaging
DTI was employed to longitudinally investigate the micro-
structural changes in the gray and white matter of the rTg4510
mice. The results within the high-ranked pathologic gray matter
tissues are shown in Fig. 5. At 7.5 months, the untreated rTg4510
mice exhibited increased FA and MD, with both parameters able to
discriminate between the untreated rTg4510 mice and wild-type
controls (Fig. 5AeD). Interestingly, at earlier time points, neither
FA (Fig. 5A and B) nor MD (Fig. 5C and D) were able to distinguish
between the rTg4510 mice and wild-type controls, suggesting that
detectable changes in these DTI parameters occur downstream
from the formation of tau lesions from 4 months.
After treatment with doxycycline from 3.5 months, we observed
no signiﬁcant difference to control values of MD in the treated
rTg4510 mice at 7.5 months (Fig. 5B). In this instance, MD readily
discriminates between the treated and untreated rTg4510mice (p<
.0001) and the untreated rTg4510 mice and wild-type controls (p <
.0001) at 7.5 months. We identiﬁed a similar pattern of results
Fig. 5. Longitudinal (A and C) fractional anisotropy and (B and D)mean diffusivity in the
high-ranked pathology regions after (A and B) 3.5 months and (C and D) 4.5 months
doxycycline intervention. Statistically signiﬁcant groups have been identiﬁed and
highlighted. Error bars represent the standard deviation. Wild-type versus untreated
rTg4510s: **p  .01, ***p  .001, and ****p  .0001. Wild-type versus treated
rTg4510s: þp  .05. Treated rTg4510s versus untreated rTg4510s: p  .001
and p  .0001.
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observed good discrimination in FA between treated and untreated
rTg4510 mice (p< .001) (Fig. 5C and D: 7.5 months). In contrast, the
thalamus presented with comparatively few signiﬁcant differences
in DTI parameters between the 2 cohorts in both longitudinal
studies (Supplementary Fig. 6).
The RD results for the white matter region in the corpus cal-
losum are shown in Fig. 6. Our ﬁndings of increased RD in the
rTg4510 mice are consistent with the previous ﬁndings in this
model (Sahara et al., 2014). The mean RD in the treated group was
less than the untreated group at 7.5 months in both longitudinalFig. 6. Longitudinal radial diffusivity in the corpus callosum after (A) 3.5 months and
(B) 4.5 months doxycycline intervention. Statistically signiﬁcant groups have been
identiﬁed and highlighted. Error bars represent the standard deviation. Wild-type
versus untreated rTg4510s: *p  .05 and **p  .01.studies and showed a trend toward wild-type values; however,
these differences were nonsigniﬁcant (Fig. 6). Similarly to FA and
MD (Fig. 5), RD is not able to distinguish between the rTg4510 mice
andwild-type controls at earlier time points, further reinforcing our
observations that the DTI parameters may not be sensitive to early
neuropathology in this model. Taken together, the pattern of FA,
MD, and RD results suggest that these DTI parameters are sensitive
to more downstream events after suppression of the tau transgene.
3.5. Cerebral blood ﬂow
We used ASL to measure CBF in the rTg4510 mice. The results
within the high-ranked pathology regions, after 3.5 and 4.5 months
doxycycline intervention, are shown in Supplementary Fig. 7. In the
4.5-month intervention study, we detected signiﬁcant elevation in
CBF in the rTg4510 mice compared with the wild-type controls (p<
.0001) (Supplementary Fig. 7B: 4.5 and 7.5 months). Unexpectedly,
this observation was not replicated in the 3.5-month intervention
study (Supplementary Fig. 7A). Blood ﬂow maps for representative
rTg4510 mice and wild-type controls at baseline and ﬁnal imaging
time points are presented in Supplementary Fig. 8, to illustrate our
ﬁndings of hyperperfusion in the rTg4510 mice at 4.5 months. This
discrepancy may be because of subtle differences in the concen-
tration of isoﬂurane, a vasodilator, between the 2 animal cohorts
(1.5%) (Drummond et al., 1986; Matta et al., 1999).
We endeavored to maintain consistency in the experimental
setup between imaging time points; this included executing the
ASL sequence within the ﬁrst 45 minutes of the mouse being
anesthetized to reduce complications because of prolonged anes-
thesia. Despite our best efforts, we believe thatmiscalibration of the
isoﬂurane vaporizer may have resulted in differences in the depth
of anesthesia. To investigate this hypothesis further, we acquired
CBF measurements at increasing concentrations of isoﬂurane in a
separate cohort of aged rTg4510 mice (9 months) and wild-type
controls. We observed a marked increase in cortical CBF (high tau
region) changing from 1.5% to 2% isoﬂurane in the rTg4510 mice but
not in the thalamus (low tau region) (Supplementary Fig. 9). This
may indicate that high-ranked tau pathology regions may be more
vulnerable to isoﬂurane-driven hyperperfusion; no signiﬁcant in-
creases in CBF were observed in the thalamus.
4. Discussion
In this work, we report the ﬁrst application of multiparametric
MRI biomarkers, including structural MRI, ASL, DTI, and APT, in a
longitudinal study of neurodegeneration in the rTg4510 mouse
model of tauopathy.
Histologic evaluation of pathologic tau revealed a distinct
pattern of regional severity, with high deposition within the cortex
and hippocampus, and milder afﬂiction of the thalamus as previ-
ously observed (Wells et al., 2015). Treatment with doxycycline
dramatically reduced the amount of PG-5 positive neurons in all the
regions analyzed, through deactivation of the promoter within the
transgene that drives tau expression and subsequent NFT formation
(SantaCruz et al., 2005). Although observed in both treatment
groups, the effect of doxycycline was more marked in the hippo-
campus and thalamus of the early (3.5 months) treatment group,
suggesting that the transgene was repressed before the accumu-
lation of signiﬁcant tau pathology in these regions. These histologic
results illustrate the efﬁcacy of the doxycycline intervention for
reducing tau accumulation.We sought to exploit the dynamic range
in tau accumulation in rTg4510 mice treated with doxycycline from
3.5 and 4.5 months, and vehicle-treated rTg4510 mice, to assess the
sensitivity of our MRI biomarkers to the development and sup-
pression of pathologic tau.
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tudinal studies of AD patients such as the Alzheimer’s Disease
Neuroimaging Initiative, which aims to identify early biomarkers
and evaluate emerging AD interventions (Jack et al., 2008). It has
been hypothesized that MR-detectable structural changes may
precede cognitive impairment in AD, supporting the clinical utility
of this technique for early diagnosis. In this work, we used struc-
tural MRI to evaluate neurodegeneration in the rTg4510 mice, in
conjunction with TBM and atlas-based parcellation. Both of these
image processing techniques offer an unbiased estimation of brain
atrophy and eliminate the need for time-consuming manual
methods for structural data analysis (Ma et al., 2014).
Our TBM results identiﬁed gross structural changes within the
rTg4510 brains, including extensive atrophy within the cortex.
Gross morphometric changes in the later stage of the disease have
previously been described in this model and substantiate our
current imaging and histologic ﬁndings (Wells et al., 2015; Yang
et al., 2011). These changes are markedly reduced after treat-
ment with doxycycline, suggesting that structural MRI is sensitive
to the suppression of pathologic tau in this model. The atlas-based
parcellation results provided quantitative regional volume esti-
mates, with detectable atrophy occurring within the high-ranked
pathology regions of the rTg4510 animals from 3.5 months.
However, this volume difference was also seen in the thalamus
(low-ranked pathology), indicating that this difference could be
because of either neurodevelopmental effects of transgene
expression during prenatal development or brain alterations and
compensation in response to the forebrain atrophy. Normalizing
the absolute volumes to total brain volume revealed a pattern of
atrophy that is speciﬁc to tau pathology and accounts for the early
global changes in brain volume. The normalized volume data
revealed deterioration of the high-ranked pathology regions
detectable at 5.5 months, proceeding the development of NFTs
within the cortex from 4 months (SantaCruz et al., 2005). We also
observed a reduction in atrophy within rTg4510 mice treated with
doxycycline; this was more apparent when treatment began at the
earlier time point of 3.5 months. Normalizing the absolute vol-
umes to total intracranial volume instead of total brain volume
may mitigate the proportional increases observed within tissues
unaffected by tau pathology.
Our results suggest that the presence of pathologic tau un-
derpins the key structural changes seen in this model. In addition to
detectable volume losses within areas expressing high tau burden,
the suppression of the tau transgene resulted in markedly reduced
atrophy, which correlates with the reduction of PG-5epositive cells
in the high-ranked pathology regions.
Our ﬁndings support the application of structural MRI as a close
correlate of tau pathology, where it has already garnered clinical
acceptance (Jack et al., 2002). In addition, we believe that structural
MRI may serve as a valuable biomarker for assessing therapies
targeting the production or clearance of pathologic tau and the
associated neurodegeneration and volume loss.
APT is a comparatively new technique for measuring the ex-
change of bulk water protons with amide protons of mobile cellular
protein (Zhou et al., 2003a, 2003b). APT is more commonly used for
imaging brain tumors (Jones et al., 2006; Zhou et al., 2003a, 2003b)
owing to its sensitivity to changes in protein expression in malig-
nant tissues (Zhou et al., 2008). In this work, we observed a
reduction in APT in high-ranked pathology regions within the
rTg4510 mice compared with wild-type controls at 7.5 months.
These changes may be caused by the presence of neuronal tau pa-
thology, impairing the chemical exchange between the amide
protons and water protons (Wells et al., 2015). No signiﬁcant dif-
ferences were observed within the thalamus, where tau pathology
was notably mild, further supporting this interpretation.Although APT aims to provide a direct measure of proton ex-
change, it is highly sensitive to changes in tissue pH. Acidiﬁcation of
the brain of AD patients has already been observed (Fang et al.,
2010) and attributed to the accumulation of acidic metabolites
and a breakdown in the brain’s ability to maintain a constant in-
ternal pH. The decreased APT within the rTg4510 mice may,
therefore, also reﬂect changes in tissue pH within the high-ranked
pathology regions. Isoﬂurane anesthesia is not believed to alter
tissue pH (Constantinides et al., 2011; Makaryus et al., 2011),
although the implications after prolonged anesthesia have yet to be
explored. To mediate any isoﬂurane-related changes in tissue pH,
the CESTacquisitionwas performed at the beginning of the imaging
protocol.
In addition to pH, the APT signal can also be inﬂuenced by the
cellular water content and the T1 relaxation time of the bulk tissue
water (McVicar et al., 2014). It is alsoworth noting that APT is highly
dependent on B0 ﬁeld homogeneity (Scheidegger et al., 2011),
especially when applied to in vivo imaging data at high magnetic
ﬁeld strengths (Sun et al., 2007); in this work, the inﬂuence of B0
ﬁeld inhomogeneities was alleviated by separately shimming over
the CEST image acquisition volume before image acquisition. It is
difﬁcult to elucidate one underlying factor that is causing the APT
changes in this model; regardless, our results illustrate the sensi-
tivity of measures of APT to tau-related pathology in this model and
may reﬂect neurodegenerative processes. In particular, it may serve
as an important biomarker when assessing the efﬁcacy of novel
therapeutics targeting pH-sensitive pathways, such as neuronal
transmitters (Anand et al., 2014).
DTI is increasingly being employed in longitudinal studies of AD
(Acosta-Cabronero et al., 2012; Mielke et al., 2009). It can offer
heightened sensitivity to changes in the gray and white matter,
which are not so readily detectable using structural MRI. It is
believed that DTI changes may precede volume changes in AD and,
therefore, may represent an important early biomarker of the dis-
ease with enhanced sensitivity to early microstructural changes
(Hugenschmidt et al., 2008).
RD is a valuable DTI parameter that reﬂects diffusion perpen-
dicular to the primary direction in a voxel, which may reﬂect ﬁber
orientation in the white matter. Our observation of increased RD in
the corpus callosum mimics the clinical picture (Huang et al., 2012)
and has been previously observed in the rTg4510 mouse (Wells
et al., 2015). Demyelination has been cited as a possible mecha-
nism underpinning this change (Sahara et al., 2014; Song et al.,
2004). This is supported by the previous work in the rTg4510
mouse, where electron microscopy revealed swollen unmyelinated
processes in the corpus callosum from 4 months (Sahara et al.,
2014). No axial diffusivity changes have been observed in this
model, suggesting that demyelination is occurring in the absence of
axonal injury (Song et al., 2002). Alterations in RD were not
signiﬁcantly different until the ﬁnal imaging time point at 7.5
months; our observations, therefore, suggest that RD may be sen-
sitive to downstream events proceeding the accumulation of
pathologic tau and unmyelinated processes from 4 months
(SantaCruz et al., 2005). Treatment with doxycycline marginally
reduced the RD changes; however, there was no marked
improvement in this parameter when treatment was commenced
earlier.
Although DTI is traditionally used to characterize white matter
structures, it can also be applied to ﬁber-rich gray matter structures
such as the hippocampus (Qin et al., 2013). We used FA and MD
within the high-ranked pathology regions of the cortex and hip-
pocampus. Our ﬁnding of increased FAwithin the rTg4510mice was
unexpected, as this traditionally implies more intact axons. How-
ever, the phenomenon of increased FA in brain regions undergoing
gross degenerative processes has previously been observed
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of isotropic cells (Kerbler et al., 2013). Meanwhile, our observation
of increased MD in the rTg4510 mice mimics the clinical condition
(Cherubini et al., 2010; Kantarci et al., 2001); this change is believed
to indicate enlargement of the extracellular space, suggesting
neurodegeneration is occurring (Cherubini et al., 2010; Sykova,
2004).
Similarly to the RD results, FA and MD in the high-ranked pa-
thology regions were only able to discriminate between the
rTg4510 mice and wild-type controls at the ﬁnal imaging time
point. However, these parameters offered heightened sensitivity to
the doxycycline treatment. After 3.5 and 4.5 months doxycycline
intervention, we identiﬁed recovery of both FA and MD, suggesting
that the presence of pathologic tau is underpinning these DTI
changes. We observed greater recovery of MD after earlier (3.5
months) treatment with doxycycline, suggesting that MD may be
more sensitive to suppression of pathologic tau.
Although it has been claimed that microstructural changes
detectable using DTI may precede structural changes (den Heijer
et al., 2012), our results do not support this hypothesis for this
model. Increased FA, MD, and RD in the rTg4510 mouse were only
detectable at 7.5 months, in the presence of signiﬁcant atrophy and
tau burden at this time point. We, therefore, propose that the
strength of DTI may not lie in its ability to discriminate between
rTg4510 mice and wild-type controls; rather, it offers valuable in-
formation that may compliment the structural MRI results. This
may be particularly beneﬁcial when assessing therapeutic efﬁcacy
of treatments that target pathways for which DTI offers heightened
sensitivity.
There is growing evidence supporting the role of CBF as a
biomarker of AD (Wolk and Detre, 2012). The vascular hypothesis
for AD stipulates that underlying vascular factors such as hyper-
tension, diabetes, and obesity may substantially contribute to the
development of AD pathogenesis (Ruitenberg et al., 2005; de la
Torre, 2004). Measurements of CBF, therefore, may represent an
important biomarker in the early diagnosis of AD and for evaluation
of therapies that may produce a vascular response (Hajjar and
Rodgers, 2013). CBF differences have already been observed in AD
patients using ASL, with decreased perfusion in cortical regions
affected by the disease (Wolk and Detre, 2012).
Previous observations in the rTg4510 mouse identiﬁed a distinct
pattern of hyperperfusion in the cortical and hippocampal regions
in an advanced stage of the pathology (Wells et al., 2015). In the 4.5-
month intervention study, we noted distinct hyperperfusion
consistent with this previous work, although this was not replicated
in the 3.5-month intervention study. To understand this further, we
investigated the effects of the anesthetic isoﬂurane in the rTg4510
mouse. We hypothesized that these discrepancies may be because
of subtle differences in the concentration of administered iso-
ﬂurane; a volatile anesthetic that has been shown to cause a dose-
dependent increases in CBF (Matta et al., 1999). This theory was
supported by evidence of hyperperfusion at high concentrations of
isoﬂurane (Drummond et al., 1986). Interestingly, we noted that
when the mice were challenged with a higher concentration of
isoﬂurane, the regions of high tau pathology responded with a
marked increase in CBF, which was much less evident in the wild-
type controls. Although it is unclear why this is the case, a recent
work demonstrates that the rTg4510 mouse has increased cere-
brovascular response (Wells et al., 2014), which could suggest that
elevated levels of blood CO2, because of the reduced respiration rate
that accompanies increased delivery of isoﬂurane, may result in the
increased CBF. Similar results have recently been observed in a
bigenic mouse model of AD, where increased cerebrovascular
response in response to hypoventilation was reported (Govaerts
et al., 2014). Furthermore, the sensitivity of the rTg450 mouse toincreased isoﬂurane concentration may be because of a breakdown
in autoregulation (Gozzi et al., 2007), a mechanism that may be
affected as a result of tau pathology, leading to vascular compen-
sation and the increase in CBF, although the precise mechanism is
still unknown (Wells et al., 2014).
A number of additional rodent studies have reported cortical
hypoperfusion using ASL in conjunction with isoﬂurane anesthesia
at varying concentrations: 1%e1.5% (Faure et al., 2011), 1.5%e2%
(Massaad et al., 2010), and 2% (Weidensteiner et al., 2009). How-
ever, these studies all focus on models exhibiting amyloid pathol-
ogy. Our observations of hyperperfusion at high concentrations of
isoﬂurane may be unique to the rTg4510 mouse and reﬂect a tau-
related effect. However, clinical blood ﬂow studies have reported
that the vasodilating properties of isoﬂurane result in redistribution
of regional CBF measurements, which must be taken into account
when interpreting our ﬁndings in the rTg4510 mouse (Villa et al.,
2012). Despite the complexity surrounding CBF measurements, at
higher concentrations of isoﬂurane, we observed complete
discrimination of the rTg4510 mice from wild-type controls, sug-
gesting it may be a useful biomarker for evaluating the rTg4510
mouse’s response to candidate therapies. However, careful cali-
bration of administered anesthetic gases is required in future
studies to extract meaningful longitudinal CBF measurements in
the rTg4510 mouse.
Previous work in the rTg4510 mouse at 8.5 months indicated
that hyperperfusion and increased MD were detectable in regions
of low tau pathology (the thalamus of the rTg4510 [mean NFT
density ¼ 2.3 cells/mm2]) (Wells et al., 2015). Thus, we considered
these biomarkers to be strong candidates for relatively early
detection of tau-driven abnormalities in the cortex and hippo-
campus of the rTg4510. However, in this work, no differences in MD
between the WT and rTg4510 cohorts were detected in the high-
rank regions at 3.5, 4.5, or 5.5 months. Increased CBF was
observed in the rTg4510 mice at baseline in the 4.5-month inter-
vention study, but this ﬁnding was not reproduced at 3.5 or 5.5
months in the 3.5-month intervention study, likely owing to dis-
crepancies in anesthetic delivery between the 2 longitudinal
studies.
Finally, it should be noted that this is a mouse model of tauop-
athy, which develops robust NFT pathology and AD-related
neuropathologic changes in the absence of amyloid plaques. In
this work, we uncovered tau-speciﬁc alterations, as this model
permits the dissection of tau’s role in the neurodegenerative
cascade. However, caution must be taken when interpreting these
ﬁndings in the context of the clinical condition, in the presence of
both plaques and NFTs.
5. Conclusions
This study demonstrates the value of non-invasive multi-
parametric quantitative MRI for longitudinal assessment of tau
pathology in the rTg4510 model and monitoring distinct properties
that reﬂect the biological responses to therapy in AD. Our imaging
protocol permits the acquisition of structural, ASL, DTI, and APT
data in a longitudinal framework within the 3-hour anesthesia
tolerance of mice (Lerch et al., 2012). The non-invasive nature of
ASL, DTI, and APT data acquisitions potentially permits relative ease
of translation to the clinical setting. However, further standardi-
zation and reﬁnement are required to provide useful diagnostic
data in a clinically feasible imaging time.
These diverse scans all offer complimentary information and
provide insight into different pathologic mechanisms occurring
within the disease process. The structural scans and analysis proved
to be the earliest biomarker, in addition to offering the highest
degree of sensitivity to the doxycycline treatment; however, over
H.E. Holmes et al. / Neurobiology of Aging 39 (2016) 184e194 193half of the imaging time is dedicated to the acquisition of the
structural data, which should be considered on interpretation.
In summary, these data represent a platform for future longi-
tudinal and therapeutic efﬁcacy studies of novel therapeutic stra-
tegies that target varying aspects of the pathology time course in
this model.
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